Please provide your email address to receive an email when new articles are posted on . Bayer HealthCare announced the FDA expanded the approval of the company’s recombinant antihemophilic factor VIII ...
The FDA has approved a new storage option for Kogenate FS (recombinant factor VIII; Bayer HealthCare). Compared with the previous three-month room temperature option, the new option allows for storage ...
Pivotal Data Show Prophylaxis Treatment with Kogenate FS Reduces the Risk of Joint Damage and Frequent Bleeds in Children with No Pre-Existing Joint Damage BERKELEY, Calif., Oct. 10 /PRNewswire/ -- ...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--March 3, 2005--Bayer Biological Products (Bayer BP) today launched www.KogenateFS.com. The new Web site seeks to educate the hemophilia community about ...
Antihemophilic Factor VIII (recombinant) 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU; per vial; lyophilized pwd for IV infusion after reconstitution; contains sucrose; preservative-free. Dosage Required ...
WHIPPANY, N.J. — Bayer HealthCare on Monday announced that the Food and Drug Administration approved the company's new indication for Bayer's Kogenate FS antihemophilic factor VIII (recombinant) for ...
Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine ...
Bayer HealthCare announced today the official launch of Kogenate® FS (Antihemophilic Factor [Recombinant], Formulated with Sucrose) in the Middle East. Kogenate® FS is Bayer’s advanced recombinant ...
February 21, 2007 — The European Commission (EC) has granted conditional approval for darunavir ethanolate, allowing its use with ritonavir and other antiretroviral drugs in the treatment of ...
A major German drug maker called off its plan to discontinue the supply of a hemophiliac drug to the South Korean market in response to the fierce protests from patients, health authorities said ...
BERKELEY, Calif., Oct 10, 2008 /PRNewswire via COMTEX/ -- Pivotal Data Show Prophylaxis Treatment with Kogenate FS Reduces the Risk of Joint Damage and Frequent Bleeds in Children with No Pre-Existing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback